Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Related Content
Red light therapy in children with myopia
April 27th 2025

Red light therapy in children with myopia

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Pediatric ocular surface reconstruction: Managing lesion excision challenges
April 23rd 2025

Pediatric ocular surface reconstruction: Managing lesion excision challenges

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease
April 8th 2025

Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease

Early-onset atopic dermatitis linked to higher risk of pediatric uveitis
April 8th 2025

Early-onset atopic dermatitis linked to higher risk of pediatric uveitis

© 2025 MJH Life Sciences

All rights reserved.